Hemab director Laura Tadvalkar resigns from board

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Terms

What change to Hemab Therapeutics (COAG) governance was disclosed?

When did Laura Tadvalkar resign from Hemab Therapeutics’ board?

Did Hemab Therapeutics report any disagreement linked to the board resignation?

Who signed the Hemab Therapeutics 8-K reporting the director resignation?

On which exchange is Hemab Therapeutics’ common stock listed under symbol COAG?

Hemab Therapeutics Holdings, Inc. reported that Laura Tadvalkar, Ph.D. has resigned from its board of directors, effective May 8, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Hemab Therapeutics Holdings, Inc. reported that Laura Tadvalkar, Ph.D. has resigned from its board of directors, effective May 8, 2026. The company states that her resignation is not related to any disagreement with Hemab on operations, policies, or practices.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Securities Exchange Act of 1934, emerging growth company, board of directors, Common stock, $0.0001 par value per share

4 terms

Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

board of directors financial

"resign as a member of the Company’s board of directors (the “Board”)"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Hemab Therapeutics disclosed that Laura Tadvalkar, Ph.D., resigned from its board of directors, effective May 8, 2026. The company stated her resignation was not due to any disagreement over operations, policies, or practices.

Laura Tadvalkar, Ph.D., resigned as a member of Hemab Therapeutics’ board of directors effective May 8, 2026. The company received her notice of resignation on that same date, according to the current report.

No, Hemab Therapeutics stated that Laura Tadvalkar’s resignation from the board was not related to any disagreement with the company regarding its operations, policies, or practices. This indicates the departure is described as non‑contentious in the report.

The 8-K was signed on behalf of Hemab Therapeutics by Benny Sørensen, M.D., Ph.D., the company’s President and Chief Executive Officer. The signature confirms the company’s authorization of the disclosure regarding the board resignation.

Hemab Therapeutics’ common stock, with a par value of $0.0001 per share, is listed on the Nasdaq Global Select Market. It trades under the ticker symbol COAG, according to the company’s registration details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/11/2026 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2026

Hemab Therapeutics Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	001-43250	41-4241952
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

101 Main Street, Suite 1220
Cambridge, Massachusetts		02142
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 553-3952

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	COAG	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately. Dr. Tadvalkar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

HEMAB THERAPEUTICS HOLDINGS, INC.

Date: May 11, 2026

/s/ Benny Sørensen, M.D., Ph.D.

Benny Sørensen, M.D., Ph.D.

President and Chief Executive Officer

3 documents